PLK2 and ovarian carcinoma: For example, high expression of tubulin beta 3 class III (TUBB3) and low expression of salt inducible kinase (SIK2), polo-like kinase 2 (PLK2) or spleen tyrosine kinase (SYK) restore the paclitaxel sensitivity of ovarian cancer cells [7–9].